Academic Journal
Q2Atherosclerosis Plus
About Atherosclerosis Plus
Atherosclerosis Plus is a scholarly journal published by Elsevier Ireland Ltd. SCImago 2025 lists it in Q2, with an SJR of 0.723 and H-index of 57.
Coverage: 2021-2026. Research categories: Cardiology and Cardiovascular Medicine (Q2); Internal Medicine (Q2).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Lipoproteins and Cardiovascular Health; Diabetes, Cardiovascular Risks, and Lipoproteins; Atherosclerosis and Cardiovascular Diseases; Cholesterol and Lipid Metabolism; Diverse Scientific and Economic Studies; Cancer, Lipids, and Metabolism.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Plasma untargeted metabolomics in coronary artery disease – Correlation with degree of obstruction
Protásio L. da Luz, Desidério Favarato, Alexandre Antônio C. Abizaid, Luiz Antonio M. Cesar et al.
2026-12 · DOI: 10.1016/j.athplu.2026.100611Lipoprotein(a) and early LDL-cholesterol target attainment after a first acute coronary syndrome: a real-world cohort study
Núria Riera-Molist, Emma Puigoriol Juvanteny, Federico Swedzky, Ester Goutan-Roura et al.
2026-12 · DOI: 10.1016/j.athplu.2026.100618The association between albuminuria and coronary atherosclerotic burden in the general population
Fredrik Bäckström Pegelow, Yi-Ting Lin, Anders Larsson, Andrei Malinovschi et al.
2026-12 · DOI: 10.1016/j.athplu.2026.100610Association between serum lipoprotein(a) levels and aortic vulnerable plaques assessed by non-obstructive general angioscopy
Keisuke Kojima, Yudai Tanaka, Katsunori Fukumoto, Yasunari Ebuchi et al.
2026-12 · DOI: 10.1016/j.athplu.2026.100603Orthopedic surgery changes aortic valve composition in ApoE−/− mice
Amber van Broekhoven, Wessel W. Fuijkschot, Ilse P.A. Zethof, Wessel N. van Wieringen et al.
2026-12 · DOI: 10.1016/j.athplu.2026.100606Real-world cardiovascular risk estimation, blood pressure and LDL-cholesterol control: Two epidemiological studies in Romania, during pandemic and post-pandemic (SNAPSHOT-Romania)
Andrea Olivia Ciobanu, Oana Vittos, Bogdan Dolofan, Nicoleta Trambitas et al.
2026-12 · DOI: 10.1016/j.athplu.2026.100573Passive E06 IgG reduces lesional PC-OxPL and macrophage accumulation in cholesterol-fed Ldlr−/− mice
Brian Trausch-Quiróz, Alexandre Normand, Xuchu Que, Elena Alekseeva et al.
2026-12 · DOI: 10.1016/j.athplu.2026.100615Very low HDL cholesterol in infectious mononucleosis with hepatitis: a real-world evidence study
Iddo Z. Ben-Dov, Alaa Danoon
2026-10 · DOI: 10.1016/j.athplu.2026.100609Clonal Hematopoiesis is Associated with Adverse Events in Patients with High-Grade Carotid Artery Stenosis
Olesya Harkot, Roland Jäger, Stephanie Kampf, Michael Gurbisz et al.
2026-10 · DOI: 10.1016/j.athplu.2026.100617Disclaimer page
2026-09 · DOI: 10.1016/j.athplu.2026.100600Delivering a National Remote Cardiologist-led Support Programme in Primary Care to Improve the Treatment and Management of Uncontrolled Lipids and Reduce Cardiovascular Risk
David Perkins, Antony D. Grayson, Matthew Shaw, Andrew Brearton et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100592TUDOR: a treatment-adjusted diagnostic algorithm for familial hypercholesterolaemia with dual external validation in 4,028 genetically confirmed cases
N. Genedy, S. Zouwail
2026-09 · DOI: 10.1016/j.athplu.2026.100590Plasma-derived small extracellular vesicle miR-660-5p as a predictor for carotid plaque vulnerability and postoperative major adverse cardiovascular event risk
Xin Xu, Taoyuan Lu, Dechao Wang, Yuanyuan Ji et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100561Associations between carotid macrovascular and retinal microvascular alterations in diabetes: Evidence synthesis and implications for risk assessment
Gentian Bajraktari, Fisnik Jashari, Per Wester, Dren Boshnjaku et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100608Putative protective role of PCSK9 variants in a multigenerational family with familial hypercholesterolemia
Sonia Rodríguez-Nóvoa, Pedro Martínez Hernández, Irene Hidalgo Mayoral, Amanda Herranz Cecilia et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100607Environmental pollution, apolipoprotein A-1 autoantibodies and cardiovascular risk: evidence from a geospatial cross-sectional study
Noé Fellay, Sabrina Pagano, Pedro Marques-Vidal, Peter Vollenweider et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100566Population-based low-density lipoprotein cholesterol (LDL-C) concentration in childhood from the Avon Longitudinal Study of Parents and Children (ALSPAC) study: developing trajectories and LDL-burden as potential safe references for treatment targets
K. Panchal., Y. Vinogradova, R. Akyea, U. Ramaswami et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100578Audit of transition outcomes after discharge from a paediatric familial hypercholesterolaemia service
C. Sherman, A. Cazeaux, N. Davis, J. Barratt et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100586CALON-FH: AlphaFold3-Derived Structural Severity Score Enables Domain-Specific ASCVD Penetrance Prediction and Mutation-Guided Treatment Selection in Familial Hypercholesterolaemia
N. Genedy
2026-09 · DOI: 10.1016/j.athplu.2026.100591Cholesterol in amyotrophic lateral sclerosis: a bystander, a biomarker, or a target?
Matteo Farè, Chiara Comi, Giulia Susanna Ferrero, Gessica Sala et al.
2026-09 · DOI: 10.1016/j.athplu.2026.100576Reviews
Community Reviews
Version History
October 4, 2026 at 9:08 pm
October 2, 2026